Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIDA-ADJ: Adjuvant Idarubicin-Lipiodol for HCC
NCT04178642Phase 2Withdrawn
- Sponsor
- CHU Montpellier
- Start
- Sep 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of idarubicin in hepatocellular carcinoma (HCC), sponsored by CHU Montpellier. Planned start Sep 2020; status: withdrawn.
02
Drugs
idarubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04178642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04178642.